Why the DroneShield (ASX:DRO), BrainChip (ASX:BRN) and Recce (ASX:RCE) share prices are rising today

The share prices of these 3 ASX growth shares have all jumped today off the back of recent announcements. All are innovators in their fields.

| More on:
Red paper plane zooming ahead of an army of white paper plane competition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Today has been very strong for a range of ASX sectors after yesterday's market fall. We've seen the share prices of a number of innovative ASX growth companies rise today, including the 3 listed below.

DroneShield Ltd (ASX: DRO)

The Droneshield share price is up by 23.33% at time of writing.

The company provides non-ballistic detect and disrupt technology for defending against drones. It recently announced it had obtained funding from the US Department of Defence (DoD) for enhancements to its DroneShieldComplete Command-and-Control (C2) system. Previously, the company had made several announcements. First, relating to sales to 2 European nations, and second, to a successful deployment in a mid-sized European airport. This has also had an impact on the company's share price.

At the conclusion of the project to enhance the DroneShieldComplete C2, the company anticipates selling additional products to the US DoD. DroneShield CEO Oleg Vornik said the project underscored the company's leadership not only as a product/sensor manufacturer, but also as an integrator of fixed site and mobile counter unmanned aircraft systems.

Recce Pharmaceuticals Ltd (ASX: RCE)

Recce (pronounced Recky) is a medical research company developing a new range of synthetic antibiotics. Unlike current approaches, Recce's products kill bacteria instead of inhibiting growth, enabling multiple use without a reduction in potency. 

Today the company announced it has selected South Australia's CMAX Clinical Research as its independent trial facility. The laboratory will conduct a phase I clinical study of Recce's lead compound RECCE 327.

This is a controlled ascending dose study of 48 healthy adult subjects, resulting in an evaluation of the safety and tolerability of the product after intravenous use. In response to the news, the Recce share price has risen by 3.14% at the time of writing. 

Brainchip Holdings Ltd (ASX: BRN)

The BrainChip share price is up by 3.33% at the time of writing, and has risen by 73.33% over the past 5 days.

BrainChip is an artificial intelligence (AI) company that has recently completed construction of the wafer of its newest product, a neuromorphic chip designed to mimic the human brain and sensory system.

The company has announced 2 proof of concept partnerships.

First, with Magik Eye Inc to combine AI with the Magik Eye's 3D sensing. This partnership will be targeting gesture recognition in a wide array of gaming and consumer products. Second, the Brainchip share price jumped 54% after the company announced a partnership with VORAGO Technologies to support a phase 1 project for NASA.

Motley Fool contributor Daryl Mather owns shares of Recce Pharmaceuticals Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

It looks set to be a decent start to the week for Aussie investors.

Read more »

A young woman does her Christmas shopping online in her lounge room at home with a Christmas tree in the background.
Share Market News

3 things ASX investors should watch this week

Christmas is coming but there's no rest for your stock portfolio. Here are the biggest developments to monitor.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Healthcare Shares

How big could the return be with CSL shares in 2024?

Could this biotech company be a market beater in 2024?

Read more »

Smiling man working on his laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave the thumbs up to these ASX shares last week. Why are they bullish?

Read more »

A mature-aged couple high-five each other as they celebrate a financial win and early retirement
Dividend Investing

How to retire early with these ASX titans

There are so many mouth-watering dividend stocks in Australia, those who want to quit work have options.

Read more »

Man sits smiling at a computer showing graphs
Broker Notes

Morgans names more of the best ASX 200 shares to buy in December

These ASX 200 shares have been given the thumbs up by analysts at Morgans in December.

Read more »

A woman looks unsure as she ladles mixture into a pan surrounded by small appliances

My 2024 warning: Don't get (completely) lost in the passive income sauce

It's easy to become fixated on BIG yields to ease the cost of living pressures next year. Here's my word…

Read more »

a diverse groups of about twenty people stand together in a crowd staring to the front with angry and annoyed looks on their faces.
Share Market News

10 popular ASX stocks that faced shareholder revolts this AGM season

Investors vented their fury and frustration over high CEO salaries amid some mostly uninspiring share price performances this year.

Read more »